Indoco Remedies Ltd

Indoco Remedies Other Announcement

Indoco Remedies disclosed an unsolicited Crisil ESG rating of 'Crisil ESG 60'. The company notes it did not engage Crisil for the assessment.

Indoco Remedies Merger & Restructuring Worth ₹0.01 Cr

Indoco Remedies will incorporate a new wholly owned subsidiary, Warren Lifesciences Private Limited, for the pharmaceutical business with an initial capital of Rs. 1 Lakh.

Value

₹0.01 Cr

Indoco Remedies Annual General Meeting

Indoco Remedies filed proceedings of its 79th AGM held on 17 September 2026. Shareholders voted on nine resolutions including dividend and borrowing limits.

Indoco Remedies Promoter Buying

Indoco Remedies promoter Aditi M. Panandikar and PAC bought 38,930 shares on the open market, raising aggregate holding to 7.30%. No transaction price is disclosed in the filing.

Promoter stake change

+0.04%

Indoco Remedies Promoter Buying: ₹0.92 Cr

Promoters Aditi M. Panandikar, Madhura Suresh Kare, Suresh G. Kare, and Aruna Suresh Kare acquired Indoco Remedies Ltd shares via market purchases, totaling ₹0.92 Crore.

Value

₹0.92 Cr

Indoco Remedies Business Update

Indoco Remedies received seven USFDA observations in Form 483 for its Plant II (Sterile) facility in Goa following an inspection from August 27 to September 4, 2026.

Indoco Remedies Promoter Buying: ₹0.1 Cr

Promoters Aditi M. Panandikar and Madhura Suresh Kare each purchased 2,000 shares of Indoco Remedies from the open market. This reflects an increased promoter stake.

Value

₹0.10 Cr

Indoco Remedies Promoter Buying

Promoters Aditi M. Panandikar and Madhura Suresh Kare acquired 10,000 equity shares of Indoco Remedies Limited. This open-market purchase increases the promoter group stake from 5.85% to 5.86%.

Indoco Remedies Promoter Buying: ₹0.24 Cr

Promoters Aditi M. Panandikar and Madhura Suresh Kare acquired a total of 10,000 equity shares of Indoco Remedies Ltd through market purchases.

Value

₹0.24 Cr

Indoco Remedies Business Update

Indoco Remedies Limited has executed a Deed of Conveyance to sell a plot of land located at Mahal Industrial Estate to Kalpataru Townships Private Limited.

Indoco Remedies Business Update

Indoco Remedies has executed a deed of conveyance to sell a land plot in Mumbai for a total consideration of ₹64 Crore.

Value

₹64.00 Cr

Indoco Remedies Other Announcement

Indoco Remedies has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-2026. The report provides disclosures on ESG, operations, and governance.

Indoco Remedies Annual Report

Indoco Remedies Limited has scheduled its 79th Annual General Meeting for September 17, 2026. The company also released its comprehensive Annual Report for the 2025-26 financial year.

Indoco Remedies Annual General Meeting

Indoco Remedies Limited fixed September 10, 2026, as the record date for a final dividend of Rs. 0.20 per share. The 79th AGM is scheduled for September 17, 2026.

Indoco Remedies Investor Presentation: Key Takeaways

Indoco Remedies reported Q1FY27 consolidated revenue of INR 4,662 million, up 8.2% YoY. Management focuses on debt reduction, operational efficiency, and scaling domestic mid-sized brands while awaiting USFDA audits.

Call

Guides 11% growth

Indoco Remedies Management Change

Indoco Remedies Limited re-appointed Ms. Aditi Panandikar as Managing Director for a five-year term. Mr. Sudhir Kadam was also appointed as Senior Management Personnel.

Execution

5 years

Indoco Remedies Q1 FY27 Results: Turns Profitable, Net Profit ₹65.4 Cr

Indoco Remedies Ltd reported revenue from operations of ₹466.2 Cr (+8.2% YoY) and net profit of ₹65.4 Cr for Q1 FY27.

Key figure

Net profit ₹65.4 Cr

Indoco Remedies Board Meeting Date

Indoco Remedies will hold a board meeting on July 28, 2026. The board will consider unaudited standalone and consolidated financial results for June quarter.

Indoco Remedies Business Update

Indoco Remedies' Goa plant successfully cleared an inspection by the Malta Medicines Authority. The facility received EU GMP certification for solid oral dosage forms.

Indoco Remedies Regulatory Approval

Indoco Remedies received EU GMP certification from German Health Authority for its Baddi plant. This approval validates compliance with European standards for international markets.

Indoco Remedies Other Announcement

Indoco Remedies submitted its Annual Secretarial Compliance Report for FY2025-26. The auditor confirmed adherence to SEBI regulations and statutory provisions without any adverse observations.

Indoco Remedies Merger & Restructuring

Indoco Remedies completed the slump sale of its Ophthalmic Division to Sunways (India) Private Limited. This strategic divestment streamlines the company's domestic and international business portfolio.

Indoco Remedies Regulatory Approval

Indoco Remedies received EU GMP certification from the Malta Medicines Authority for its Baddi facility. This approval validates compliance with global quality standards for international markets.

Indoco Remedies Earnings Call: Key Takeaways

Indoco Remedies reported recovery in Q4FY26, driven by 94.6% growth in international formulations. Consolidated revenue reached ₹4,559 million with EBITDA margins improving to 10.9%.

Indoco Remedies Dividend

Indoco Remedies recommended a final dividend of Rs. 0.2 per equity share for FY 2025-26. The record date will be announced later.

Indoco Remedies Q4 FY26 Results: Net Loss of ₹23.7 Cr, Loss Narrows

Indoco Remedies Ltd reported revenue from operations of ₹475.6 Cr (+21.9% YoY) and a net loss of ₹23.7 Cr for Q4 FY26.

Key figure

Net loss ₹23.7 Cr

Indoco Remedies Financial Results

Indoco Remedies Limited reported Q4 FY26 results with consolidated revenues growing 26% YoY to ₹429.1 Crore. The Board recommended a dividend of ₹0.20 per share (10%) on a face value of ₹2. Growth was primarily driven by strong performance in the International Formulations business and steady API growth.

Value

₹0.20 Cr

Indoco Remedies Merger & Restructuring Worth ₹110 Cr

Indoco Remedies Limited has agreed to sell its Ophthalmic Division to Sunways (India) Private Limited for ₹110 Crore. The cash transaction is a slump sale aimed at focusing on core therapeutic areas. The division contributed approximately 3.2% to the company's standalone revenue for FY 2024-2025.

Value

₹110.0 Cr

Execution

Expected completion by 2026-07-31

Indoco Remedies Merger & Restructuring Worth ₹110 Cr

Indoco Remedies is selling its Ophthalmic Division in India and several African territories to Sunways (India) Private Limited for ₹110 Crore. The transaction, executed via a slump sale, is expected to conclude within three months. This strategic divestment allows the company to focus on its core therapeutic areas.

Value

₹110.0 Cr

Execution

Approximately 3 months

Indoco Remedies Merger & Restructuring

Indoco Remedies Limited approved the strategic transfer of its ophthalmic division in India and select African territories to Sunways (India) Private Limited. The divestment allows Indoco to focus on core therapeutic areas while Sunways strengthens its specialized ophthalmology platform. The transaction includes an established operating portfolio and manufacturing capabilities.